MK-801 Stats & Data

Microgram-to-low-milligram potency demands accurate measurement: use true 0.1 mg resolution or, preferably, volumetric dosing (e.g., 10 mg in 100 mL = 0.1 mg/mL), pre-mark oral syringes, and lock away the remainder before dosing. Long, sometimes biphasic course (often a very late peak and a very long tail) plus severe amnesia can make redosing hazardous; several users report a strong compulsion to redose—remove access to stash and use a sober sitter. Duration commonly exceeds 24 h; plan no driving, machinery, or safety-critical tasks for at least 36–48 h after dosing. Insomnia and agitation are frequent during offset; avoid self-sedating with alcohol or benzos given additive respiratory/CNS depression—seek medical care if severe. Animal studies show rapid NMDA-antagonist vacuolization with high-dose MK-801; human relevance is uncertain but avoiding heavy doses/combos and spacing sessions remains prudent. Injection (IM) has unique risks (sterility, solvent, pH); multiple anecdotal abscess/necrosis cases—best avoided outside clinical settings. Because enantiomer and salt forms can differ in potency and time-course, do not assume one vendor’s dose applies to another. Use reagent/lab testing where available; misidentified dissociatives circulate. First exposure: ≤0.25 mg single dose, no redose, and allow ≥14 days between trials. Maintain hydration and electrolytes, keep ambient temperature comfortable, and ensure a secure, supervised environment with minimal navigation hazards.